Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today

OMAHA, Neb., May 12, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:

To access the call via telephone, call 800-895-0198 from the U.S. or Canada or 785-424-1053 for international participants and enter conference ID TRANS.  A telephone replay will be available from 6:00 p.m. Eastern Time May 12, 2011 through 11:59 p.m. Eastern Time on May 26, 2011 by dialing 800-374-0328 (domestic) or 402-220-0663 (international).

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomic analyses.  Transgenomic, Inc. is comprised of 3 different divisions.  Transgenomic Molecular Lab specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases.  Transgenomic Pharmacogenomic Services is a contract research service offering translational research and clinical trial services to pharmaceutical companies in support of pre-clinical and phase I, II and III clinical trials.  Transgenomic's Diagnostic Tools Business product offerings include systems for the automation of sample processing and analysis for Cytogenetic and Molecular Diagnostic testing.  Transgenomic's WAVE® Systems and associated consumables are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification.  SURVEYOR® Scan Mutation Detection kits provide reagents and protocols for high sensitivity detection of mutations in key cancer pathway genes. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses.  Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing across all business lines by leveraging core technologies, experience and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new intellectual property to extend its offerings in molecular diagnostics and pharmacogenomic services.

SOURCE Transgenomic, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED